COAG · Hemab Therapeutics Holdings Inc. Common Stock
View on chartInsiders & Stakes
| RA CAPITAL MANAGEMENT, L.P. Director | ▲ Buy | Open Market | 6,444,637 Shares held | 6/16/2026 | View profile |
| Novo Holdings A/S 10% Owner | ▼ Sell | Other | 4,180,550 Shares held | 5/4/2026 | View profile |
| John Maraganore Director | ▼ Sell | Other | 35,948 Shares held | 5/4/2026 | View profile |
Transaction History
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 61,523 | $1.5M | 6/16/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 6,146 | $153K | 6/15/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 996 | $25K | 5/20/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 3,802 | $95K | 5/19/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 6,387 | $159K | 5/12/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 14,149 | $346K | 5/11/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 25,720 | $643K | 5/11/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 1,483 | $37K | 5/8/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 7,921 | $193K | 5/7/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 1,985 | $50K | 5/7/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 14,611 | $347K | 5/6/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 53,407 | $1.3M | 5/6/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 87,143 | $2.1M | 5/5/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 10,268 | $257K | 5/5/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 1,009,052 | — | 5/4/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 221,188 | — | 5/4/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 2,541,250 | $45.7M | 5/4/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 133,750 | $2.4M | 5/4/2026 |
| Novo Holdings A/S | ▼ Sell | Other | 4,180,550 | — | 5/4/2026 |
| John Maraganore | ▼ Sell | Other | 17,974 | — | 5/4/2026 |
| John Maraganore | ▼ Sell | Other | 17,974 | — | 5/4/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 3,607,846 | — | 5/4/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Rodman & Renshaw initiates coverage on Hemab Therapeutics
Rodman & Renshaw has begun tracking Hemab Therapeutics, assigning a Buy rating and a price target of $56. This is a new entry in the analyst coverage for the stock, which currently trades near its 52-week low. The firm's target is slightly below the current average analyst estimate of $61.20.
Rodman & Renshaw initiates coverage on Hemab Therapeutics. Rodman & Renshaw has begun tracking Hemab Therapeutics, assigning a Buy rating and a price target of $56. This is a new entry in the analyst coverage for the stock, which currently trades near its 52-week low. The firm's target is slightly below the current average analyst estimate of $61.20.